- Clene Inc (NASDAQ:CLNN) announced new results showing preserved ALS patient functional score (ALSFRS-R) and delayed time to clinical worsening from the most recent 12-month data cut of the open-label extension (OLE) of the Phase 2 RESCUE ALS trial in people with early amyotrophic lateral sclerosis (ALS) treated with CNM-Au8.
- CNM-Au8 preserved physical function when given over 48 weeks as measured by the ALSFRS-R, a clinical assessment measuring activities such as walking, speaking, breathing, feeding, and dressing independently.
- Related: Clene Shares Move Higher On Encouraging Data From Multiple Sclerosis Candidate.
- Significant preservation of function (ALSFRS-R) from randomization to 48 weeks was observed, with significant preservation of function during the long-term open-label extension (OLE) week 24 to 120 weeks from randomization.
- Significantly reduced risk of ALS clinical worsening by 52% over 120 weeks.
- CNM-Au8 treatment was well-tolerated without long-term safety concerns.
- Price Action: CLNN shares are up 4.17% at $1.25 on the last check Monday.
Reported Earlier, SAB Biotherapeutics Receives Australian Approval To Commence Phase 1 Clinical Trial Of SAB-142, A Potential Disease-Modifying Treatment For Type 1 Diabetes
Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1 clinical study of SAB-142, the first fully human anti-thymocyte immunoglobulin (ATG)SAB-142 directly targets
